Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Change in Accured Expenses (2021 - 2025)

Historic Change in Accured Expenses for Krystal Biotech (KRYS) over the last 5 years, with Q3 2025 value amounting to $5.9 million.

  • Krystal Biotech's Change in Accured Expenses rose 20468.59% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.8 million, marking a year-over-year increase of 89314.9%. This contributed to the annual value of $5.4 million for FY2024, which is 1827.56% up from last year.
  • Krystal Biotech's Change in Accured Expenses amounted to $5.9 million in Q3 2025, which was up 20468.59% from -$1.3 million recorded in Q2 2025.
  • Krystal Biotech's 5-year Change in Accured Expenses high stood at $7.5 million for Q4 2024, and its period low was -$5.2 million during Q1 2024.
  • Over the past 5 years, Krystal Biotech's median Change in Accured Expenses value was $1.9 million (recorded in 2024), while the average stood at $1.4 million.
  • In the last 5 years, Krystal Biotech's Change in Accured Expenses skyrocketed by 62934.78% in 2022 and then plummeted by 27203.18% in 2023.
  • Quarter analysis of 5 years shows Krystal Biotech's Change in Accured Expenses stood at -$4.0 million in 2021, then soared by 153.64% to $2.2 million in 2022, then surged by 70.75% to $3.7 million in 2023, then soared by 103.18% to $7.5 million in 2024, then decreased by 20.93% to $5.9 million in 2025.
  • Its Change in Accured Expenses was $5.9 million in Q3 2025, compared to -$1.3 million in Q2 2025 and $3.7 million in Q1 2025.